CompuVax Overview

  • Founded
  • 2013
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

CompuVax General Information


Developer of a proprietary recombinant, self-assembling nanoparticle platform designed to create novel antibody therapeutics. The company's platform can engineer antibodies directly, employing similar computational and directed evolution methods, enabling users to get a unique tool to discover high-affinity antibodies.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 1155 Camino del Mar
  • Suite 502
  • Del Mar, CA 92014
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CompuVax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 13-Dec-2019 000 Completed Out of Business
1. Early Stage VC (Series A1) 10-Sep-2015 000 000 000 Completed Generating Revenue
To view CompuVax’s complete valuation and funding history, request access »

CompuVax Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view CompuVax’s complete cap table history, request access »